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AbstrACt
Objectives To compare necrotising enterocolitis (NEC) 
prevention practices and NEC associated factors between 
units from eight countries of the International Network for 
Evaluation of Outcomes of Neonates, and to assess their 
association with surgical NEC rates.
Design Prospective unit-level survey combined with 
retrospective cohort study.
setting Neonatal intensive care units in Australia/
New Zealand, Canada, Finland, Israel, Spain, Sweden, 
Switzerland and Tuscany (Italy).
Patients Extremely preterm infants born between 240 
to 286 weeks’ gestation, with birth weights<1500 g, and 
admitted between 2014–2015.
Exposures NEC prevention practices (probiotics, feeding, 
donor milk) using responses of an on-line pre-piloted 
questionnaire containing 10 questions and factors 
associated with NEC in literature (antenatal steroids, 
c-section, indomethacin treated patent ductus arteriosus 
and sepsis) using cohort data.
Outcome measures Surgical NEC rates and death 
following NEC using cohort data.
results The survey response rate was 91% (153 units). 
Both probiotic provision and donor milk availability varied 
between 0%–100% among networks whereas feeding 
initiation and advancement rates were similar in most 
networks. The 9792 infants included in the cohort study to 
link survey results and cohort outcomes, revealed similar 
baseline characteristics but considerable differences 
in factors associated with NEC between networks. 397 
(4.1%) neonates underwent NEC surgery, ranging from 
2.4%–8.4% between networks. Standardised ratios for 
surgical NEC were lower for Australia/New Zealand, higher 
for Spain, and comparable for the remaining six networks.
Conclusions The variation in implementation of NEC 
prevention practices and in factors associated with NEC 
in literature could not be associated with the variation in 
surgical NEC incidence. This corroborates the current lack 
of consensus surrounding the use of preventive strategies 
for NEC and emphasises the need for research.
IntrODuCtIOn
Necrotising enterocolitis (NEC) remains a 
potentially devastating complication with 
variable treatment success rates. In the USA 
and Canada, NEC affects approximately 7% 
of babies weighing between 500–1500 g with 
approximately 20%–30% of mortality rate.1 
A recent systematic review revealed similar 
or lower incidence rates for Japan (1.6%), 
Italy (3%), Korea (6.4%) and Spain (6.9%) 
for infants born <1500 g.2 In a study from the 
strengths and limitations of this study
 ► We report on a large, multinational patient database 
and high survey response rate, enabling a snapshot 
of contemporary necrotising enterocolitis outcome 
and practices.
 ► Survey was completed by a single representative at 
each site rather than all practitioners, whereas re-
sponses were based on neonatal intensive care unit 
policies rather than personal opinion.
 ► As individual patient data for NEC prevention were 
not available, we applied a pragmatic approach link-
ing unit level survey data on prevention with patient 
level cohort data on outcome and risk factors to re-
port on a possible association between NEC preven-
tion and outcome.
 ► When linking survey with cohort study data we have 
assumed that all neonates within a unit were treated 
equally, which is an assumption and needs confir-
mation but is acceptable for generating a hypothesis.
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National Institute of Child Health and Human Devel-
opment (NICHD) of extremely preterm infants born 
between 2000–2011, NEC related deaths rose from 23% 
to 30%, whereas overall mortality declined.3 In survivors, 
NEC and surgery for NEC have been associated with 
increased risk of adverse neurodevelopmental outcome 
at 2 years of age.4–6 The financial impact of NEC is esti-
mated at US$1 billion per year in the USA alone.7
NEC is considered a multifactorial disease that results in 
profound inflammation and intestinal injury.7 8 Research 
in preventive measures is progressing but a unanimously 
accepted approach is yet to be identified. Probiotics 
supplementation reduced rates of NEC in multiple 
studies; however, results of two large randomised clinical 
trials are contradictory with no consensus on which probi-
otic may effectively prevent NEC.9 10 Donor milk and 
exclusive human milk diets are also proposed as preven-
tive measures, however, the evidence for NEC reduction 
is tentative at best.11 12 Early initiation and rapid advance-
ment of feeds have not been shown to cause harm, but 
standard practice in many units has not changed due to 
fear of NEC.13
In this context, our objective was to investigate what 
the uptake of preventative approaches at various units 
was and whether different approaches to prevention and 
different incidences of factors associated with NEC in 
literature were associated also with variations in the inci-
dence of surgical NEC in the participating eight high-in-
come countries.
MEthODs
study design, questionnaire and population
In this mixed methods study, we used a survey to deter-
mine unit level NEC prevention practices in each country, 
and a retrospective patient cohort to obtain patient level 
NEC associated factors and rates for surgical NEC and 
mortality following NEC.
Survey (unit level data)
In 2016, an online pre-piloted, anonymous questionnaire 
was sent to the directors of 168 tertiary neonatal intensive 
care units (NICUs) from eight collaborating networks: 
Australia/New Zealand Neonatal Network, Canadian 
Neonatal Network, Finish Medical Birth Register, Israel 
Neonatal Network, Spanish Neonatal Network, Swedish 
Neonatal Quality Register (SNQ), Swiss Neonatal 
Network and the Tuscany Neonatal Network in Italy. 
The questionnaire contained questions about treatment 
practices relating to extremely preterm infants under 29 
weeks’ gestation. The methodology for this survey was as 
published previously.14 Reminders were sent twice (at a 
monthly interval) to units that did not respond. The survey 
was first sent in August 2016 and was closed in December 
2016. Responders were instructed to answer all questions 
based on their practices in the year 2015. One response 
per unit (usually the director) was collected. The 10 ques-
tions relevant to NEC comprised four domains, including 
probiotic usage (five questions), start and advancement of 
enteral feeding (three questions), donor-milk availability 
and donor-milk handling (two questions). The survey was 
distributed in English and is provided as a supplementary 
file (see online supplement 1).
Cohort study (patient level data)
Patient data collected from infants born between 240 
to 286 weeks’ gestation, weighing <1500 g and admitted 
to same neonatal units between 1 January 2014 and 31 
December 2015 were compared between the eight partic-
ipating countries. Extremely preterm infants of <24 
weeks’ gestation were excluded from the current study, as 
admission to care and care provision to such infants varies 
considerably among the eight collaborating countries. 
Infants with major congenital anomalies and those born 
outside any of the participating hospitals and admitted 
after 1 week of age were excluded, as these infants may 
not have received all described preventive measures.
All networks have obtained ethical/regulatory approval 
or its equivalent from their local granting agencies to 
allow for de-identified data to be collated and sent to the 
International Network for Evaluation of Outcomes of 
Neonates (iNeo) Coordinating Centre. Overall coordina-
tion of the project is also approved by the Research Ethics 
Board at the Mount Sinai Hospital, Toronto, Ontario 
Canada for the development, compilation, hosting and 
management of the iNeo dataset at the MiCare Research 
Centre (12–0336-E). Privacy and confidentiality of patient 
data is of prime importance to the iNeo collaboration and 
data handling is in accordance with the Privacy Commis-
sioner’s guidelines.
Covariate definitions
Gestational age (GA) was determined by the best esti-
mate based on early prenatal ultrasound, last menstrual 
period, or physical examination of infants at birth, in that 
order. Birth weight z scores were calculated relative to 
population-specific and sex-specific birth weight for GA 
references selected by each network as most appropriate 
for the comparison. Antenatal steroid use was defined as 
any administration before birth, regardless of the time 
interval, patent ductus arteriosus (PDA) by clinical or 
echocardiographic diagnosis and sepsis by clear clinical 
evidence of infection as well as at least one relevant posi-
tive result from blood or cerebral fluid cultures.
Outcomes and measures
A lack of consensus on defining NEC among the eight 
participating countries led us to use surgical NEC as 
primary outcome. Surgical NEC was defined as lapa-
rotomy, laparoscopy, bowel resection, or intraperitoneal 
drain placement for NEC or suspected NEC. Indication 
to operate was pneumoperitoneum or clinical deteriora-
tion despite maximal medical therapy.15–17 Using surgical 
NEC as primary outcome also allows exclusion of poten-
tial cases of spontaneous intestinal perforations (SIP) 
as they can be identified reliably only at surgery, unless 
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the surgery was limited to peritoneal drainage. Mortality 
following NEC was defined as death after receiving a 
diagnosis of NEC stage 2 or above, according to Bell’s 
criteria,18 and was analysed to ensure that the comparison 
of surgical NEC among countries was not biased by a high 
proportion of potential surgical NEC cases missing due to 
higher NEC death rates. As Sweden does not collect NEC 
data according to Bell's criteria, its mortality following 
NEC may be somewhat lower than reported.
statistical analysis
Unit level analyses
Unit level survey responses were reported using descrip-
tive statistics and reported as percentages or displayed 
graphically.
Mixed level analyses
Unit level data for preventative approaches of probiotic 
usage, early feeding and donor milk availability were 
analysed for their association with patient level data of 
surgical NEC. A multi-level logistic regression model was 
developed with surgical NEC as dependent variable, and 
unit-level practices (probiotics, early feeding and donor 
milk use) and individual patient level data (GA, male sex, 
multiple births and birth-weight z-score) as independent 
variables. Adjusted ORs and 95% CI were calculated. This 
analysis was not possible for Australia/New Zealand and 
Spain, as permission for linking survey information and 
patient data were not available. No model could be devel-
oped for networks where all units provided any of the 
prophylactic approach to all or to none of their patients. 
Generalised estimation equation was used to account for 
auto-correlation within units.
Patient level analyses
Patient level data were used to calculate variations in base-
line characteristics, factors associated with NEC in liter-
ature, surgical NEC rates and mortality following NEC 
for participating networks. Standardised ratios (SRs) for 
participating networks were calculated as the observed 
number of infants who received NEC surgery divided by 
the number of infants expected to receive NEC surgery, 
based on the sum of predicted probabilities from a multi-
variable adjusted logistic regression model using data from 
all other countries in the study. Adjustment was made for 
the same parameters as for the ORs. Standardised ratio 
(SR) estimates were graphically displayed. As the SR esti-
mates are calculated in relation to all other countries 
combined, it is not directly comparable between contrib-
utors. Data management and statistical analyses were 
performed at the iNeo Coordinating Centre in Toronto, 
Canada using SAS V.9.2 (SAS Institute).
Patient and public involvement
This study used de-identified data. Patients or public were 
not involved in the development of the research question, 
the outcome measures or the study design. The results 
of this study will be disseminated to the public via the 
iNeo-website ( www. ineonetwork. org) and to the parent 
groups of the individual networks.
rEsults
unit level analyses of survey
Probiotics
Out of a total of 168 network units, 153 (91%) responded 
to the online survey (table 1). Probiotic provision for 
infants born <29 weeks’ gestation ranged from 0% of units 
in Israel and Sweden to 100% of units in Finland. Among 
units providing probiotics, initiation of therapy ranged 
from 0 to 3 days of age in most units. Lactobacillus and/
or Bifidobacterium were the preferred probiotic species; 
however, other species were provided as well (see online 
supplement 2). In most units in Australia/New Zealand, 
Finland and Tuscany, probiotic supplementation was 
continued in cases of culture positive sepsis, whereas most 
units in Switzerland stopped providing probiotics.
Enteral feeding
Table 1 summarises enteral feeding initiation and 
advancement practices for infants <26 weeks’ gestation 
and between 26–28 weeks’ gestation. Figure 1 summarises 
feeding initiation in both age groups. The majority of 
units began enteral feeding on first or second day of life. 
In Finland, Sweden and Switzerland, all units reported 
initiating feeding on first day of life. There was some vari-
ation in daily rates of advancement between and within 
all networks, with a majority of units advancing at rates 
between 10 to 25 mL/kg/day. No overall preference in 
enteral feeding volume was seen in infants who received 
milk fortifier, with a range in administration varying 
between 70–120 mL/kg/day.
Donor Milk
Donor milk availability ranged between 0% of units in 
Israel to 100% of units in Finland, Sweden and Tuscany. 
A majority of units in Spain, Switzerland and Tuscany 
had initiation criteria at <32 weeks’ gestation or <1501 g 
weight, whereas in Sweden most units provided donor 
milk at <34 weeks’ gestation. No uniform stopping criteria 
for donor milk use were applied by most units, except for 
Tuscany where the majority of units stopped at 1800 g. 
Units in Finland and Spain used variable criteria other 
than age or weight for starting and stopping donor milk 
provision.
Mixed level analyses of surveyed practices and surgical nEC
Probiotics: We could only compare units in Canada which 
showed no difference in surgical NEC with probiotics 
and Switzerland which showed lower odds with probiotics 
(table 1). The adjusted OR combining all units from the 
six networks allowing linkage between unit survey and 
cohort study revealed no significant association of probi-
otics provision with surgical NEC (0.84, 95% CI 0.61 to 
1.16).
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Figure 1 Routine start of enteral feeding for extremely 
preterm infants. Bubble chart displaying routine start of 
enteral feeding for network infants<26 weeks’ gestation 
and 26–28 weeks’ gestation. Circle size corresponds 
to proportion of units per network with routine start of 
enteral feeding at any given day. ANZNN, Australian and 
New Zealand neonatal network; CNN, Canadian Neonatal 
Network; FinMBR, Finnish medical birth register; GA, 
gestational age; INN, Israel Neonatal Network; PD, physician 
dependent; SEN1500, Spanish neonatal network; SNQ, 
Swedish Neonatal Quality Register; SwissNeoNet, Swiss 
neonatal network; TuscanNN, Tuscan neonatal network.
Early initiation of feeding: Data from Canada, Israel and 
Tuscany were available for comparative analyses (table 1). 
Except for neonates of 26–28 weeks’ GA in Tuscany there 
was no difference in odds of surgical NEC in group who 
were initiated feeds on day of birth compared with units 
which started feeds later. The adjusted OR combining 
all units providing enteral feeding on day 0 revealed no 
significant association to surgical NEC (1.16, 95% CI 0.83 
to 1.63).
Donor milk: Data from Canada and Switzerland were 
available for comparative analyses. There was no differ-
ence in odds of surgical NEC between units which 
provided donor milk compared with those units which 
did not provide donor milk. The adjusted OR combining 
all units also revealed no association (table 1).
Patient level analyses of cohort study
A total of 9792 infants were included in the analysis. The 
baseline characteristics in table 2 reveal a small varia-
tion among networks in their overall mean GA (range 
26.3–26.5 weeks), mean birth weight z-score (−0.22 to 
+0.18), SGA-ratios (8.8%–12.8%) and male sex distribu-
tion (51.5%–55.3%). There was considerable variation 
between networks among factors associated with NEC 
in literature: receipt of antenatal steroids ranged from 
82.9% in Israel to 97.3% in Finland, caesarean section 
ranged from 60.0% in Canada to 82.7% in Switzerland, 
PDA treated with indomethacin ranged from 0% in coun-
tries exclusively administering ibuprofen or paracetamol 
to treat PDA (Spain, Sweden, Tuscany) to 39.6% in Swit-
zerland and sepsis ranged from 14.6% in Switzerland to 
46.2% in Spain.
Overall, average surgical NEC incidence rate in all 
countries combined was 4.1%, (ranging from 2.4% in 
Australia and New Zealand and 8.4% in Spain) whereas 
death following NEC diagnosis occurred in 2.4% of all 
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Figure 2 Necrotising enterocolitis surgery prevalence rate 
and 95% CI by network for 2014–2015. ANZNN, Australian 
and New Zealand neonatal network; CNN, Canadian 
Neonatal Network; FinMBR, Finnish medical birth register; 
INN, Israel Neonatal Network; NEC, necrotising enterocolitis; 
SEN1500, Spanish neonatal network; SNQ, Swedish 
Neonatal Quality Register; SwissNeoNet, Swiss neonatal 
network; TuscanNN, Tuscan neonatal network.
Figure 3 Standardised ratios for surgically treated 
necrotising enterocolitis from 2014 to 2015. Standardised 
ratios were adjusted for: gestational age, male sex, multiple 
birth and birth-weight z-score. abbreviations: ANZNN, 
Australian and New Zealand neonatal network; CNN, 
Canadian Neonatal Network; FinMBR, Finnish medical birth 
register; INN, Israel Neonatal Network; SEN1500, Spanish 
neonatal network; SNQ, Swedish Neonatal Quality Register; 
SwissNeoNet, Swiss neonatal network; SR, standardised 
ratio; TuscanNN, Tuscan neonatal network.
infants (ranging from 1.4% in Sweden to 3.3% in Spain) 
(table 2, figure 2). As none of the countries had higher 
rates of mortality following NEC in relation to their 
surgical NEC incidence rate, we ruled out the possibility 
that the surgical NEC incidence rate of any country is 
under-reported due to death before surgery can take 
place. Australia/New Zealand had lowest adjusted stan-
dardised ratios for surgical NEC whereas Spain had the 
highest standardised ratio among participating networks 
(figure 3).
DIsCussIOn
In this large multi-centre, multi-national, mixed methods 
study linking unit level survey and retrospective patient 
level cohort data, we identified that, on a unit level, 
NEC preventive practices of using probiotics or donor 
milk varied from 0%–100% between networks, whereas 
feeding start age and advancement had minor variation 
between the units of each network. In mixed level anal-
yses, probiotics were associated with reduced odds of 
surgical NEC in Switzerland and early feeding was asso-
ciated with reduced odds of surgical NEC in Tuscany for 
neonates of 26–28 weeks’ gestation. Donor milk provision 
was not associated with surgical NEC. Patient level anal-
yses revealed that 1 in every 25 admitted infants at 24–28 
weeks’ gestation received surgical intervention for NEC 
with some variation between networks in incidence and 
NEC associated mortality. Standardised ratios for surgical 
NEC were lower in Australia/New Zealand, higher in 
Spain and comparable for the remaining six networks.
Multiple meta-analyses of randomised studies have 
shown that probiotics are associated with reduced rates 
of NEC and sepsis.19 20 However, a lack of consensus 
regarding the strain(s), dose and duration and timing 
of use has prevented many units from adopting it as a 
strategy. Moreover, the long-term effects on immune 
function and metabolism following replacement of a 
maternally derived intestinal microbiome with a domi-
nant exogenous bacterial species is not known.21 The 
wide variation in units that participated in this study 
regarding their use, strains, start and stop time and the 
lack of association with surgical NEC rate may be due to 
the very high-risk population, different strains and the fact 
that this study involves the entire population at unit-level 
rather than a select population enrolled in randomised 
trial. The difference in results between systematic reviews 
and this study could be due to pooling of inhomogeneous 
studies into meta-analyses as concerns raised by several 
investigators indicate. Further pragmatic studies from 
multiple countries are needed.
There is evidence that implementing evidence-based 
standardised feeding guidelines reduces the incidence 
of NEC.8 Although such guidelines are not uniform, they 
have generally incorporated an early minimal enteral 
nutrition phase during which 10–20 mL/kg/d of enteral 
nutrition is provided without increase, followed by daily 
advancement based on continued tolerance. Older prac-
tices withheld feedings for days to weeks after birth in an 
attempt to avoid an assumed association of NEC with the 
start of enteral feeding.22 The majority of units among the 
eight participating countries initiate early feeding with 
rapid rates of advancement, with few units continuing 
to favour the slower approach. We found no association 
between feeding start and surgical NEC. This may be due 
to the very small number of units which delay feeds.
Although using donor milk in lieu of formula feed-
ings has led to reduced NEC rates in recent studies, it is 
unclear whether donor milk itself protected against NEC 
or whether the avoidance of formula acted as a protective 
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factor.8 We identified a large variation between networks 
regarding availability and provision of donor milk and 
varying preferences for initiation and stopping criteria. 
At unit level analyses, there was no association between 
donor milk and surgical NEC. One explanation may be 
that units without donor milk available may actually have 
a more active programme to help mothers provide breast 
milk.
Recent publications, several of them population-based, 
report NEC rates for very low birth weight infants (VLBW, 
500–1500 g) in the range of 2%–12%.15 23–28 In a previous 
review, variations in rates across different NICHD centres 
and periods ranged from 1%–22% of VLBW infants 
between 1987–2000.29 Reported mortality of infants 
with NEC continues to remain high at approximately 
15%–30%.15 30 Incidences of surgical intervention are less 
often reported but usually occur in 30%–50% of patients 
acquiring NEC.15 16 28 31 Considering these rates, the 
proportions of surgical NEC and death following NEC 
diagnosis in the current study are within the middle to 
upper range of previously published values, as expected 
given the lower GA range (240–286) of our study versus 
previously reported VLBW references. They correlate 
well with the NEC rates reported for infants<28 weeks GA 
in a recent review.2
The risk of acquiring NEC is inversely proportional 
to GA.8 16 31–34 Fetal growth restriction and male sex may 
be additional risk factors.27 31 In our study, GA and birth 
weight z-score were comparable and therefore they did 
not explain outcome variation between networks. Given 
the association between NEC and antenatal steroid 
administration,23 31 35 caesarean section,34 36 37 sepsis6 16 38 
and PDA treated with indomethacin,36 39 40 we expected 
surgical NEC incidence to be affected by the variation of 
these factors between networks. However, there was no 
association in networks with up to 10% lower proportions 
of antenatal steroid use (Sweden, Israel), up to 17% lower 
proportions of vaginal delivery (Switzerland), and up to 
twice as many indomethacin-treated PDA patients (Swit-
zerland). The only association observed was for the two 
networks with the highest proportions of surgical NEC 
(Tuscany, Spain), which also had the highest proportions 
of sepsis. This is noteworthy as it is known that sepsis 
and NEC can occur concurrently. But it is at times very 
difficult to differentiate which complication occurred 
first. It is possible that sepsis triggered the inflamma-
tory response and may have led to ischaemia and on the 
other hand ischaemic bowel with increased permeability 
allowed translocation of bacteria from intestine into 
the blood stream.4 24 Our result highlights the need for 
increased efforts for prevention of infection in general 
for improved outcome of preterm neonates.
The lack of consensus on defining NEC has led to vari-
able definitions in research databases and clinical trials.41 
This challenge is reflected in the participating eight 
networks as well, where most networks used Bell's stage 
2 as the defining threshold, while one network included 
‘mild’ or ‘initial’ cases, corresponding to Bell’s stage 1.18 
The current study therefore included iNeo networks 
collecting data on surgical NEC based on laparotomy 
or drainage, according to the accepted indication to 
operate in cases of pneumoperitoneum or clinical dete-
rioration despite maximal medical therapy.15–17 Neverthe-
less, variation in threshold to operate in NEC may exist 
and contribute to variations in surgical NEC. The study 
is further restricted to infants<29 weeks’ gestation whose 
risk of acquiring NEC is enhanced and who are more 
likely to have a common pathogenesis.33 34 41
The current study is strengthened by the large, multi-
national patient database and high survey response rate, 
enabling a snapshot of contemporary outcome and prac-
tices. However, not all reporting networks are population 
based.42 Moreover, the survey was completed by a single 
representative at each site rather than all practitioners, 
but responses were based on NICU policies rather than 
personal opinion. We would have liked the analyses of 
individual per patient practices as this would have been 
the most ideal pragmatic scenario; however, in our data-
base these items are not collected. Thus, in linking survey 
with cohort study we have assumed that all neonates 
within a unit were treated equally, which is an assump-
tion and needs confirmation. However, it is acceptable 
for generating a hypothesis. Also, NEC-related mortality 
was based on Bell stage 2 even though the networks were 
not certain on whether all units reported NEC as of 
stage 2 only and did not by mistake also report on NEC 
stage I in some cases which are assumed to be excep-
tions. This uncertainty however led to our decision not 
to evaluate NEC stage 2 as primary outcome but instead 
revert to the more robust outcome of NEC surgery as 
primary outcome. The networks were however confident, 
that the reported NEC-related mortality predominantly 
based on Bell's stage 2 was accurate enough to rule out 
a large survival bias. Another limitation could arise if 
NEC surgery is limited to peritoneal drainage in a patient 
because without laparotomy, a differentiation between 
NEC and SIP cannot be made. In the context of this 
study, this is relevant as probiotic treatment would not be 
expected to influence SIP and a high SIP contamination 
could therefore bias the study results concerning probi-
otics. We however believe the effect of this bias to be small 
as the number of neonates with NEC exclusively managed 
by peritoneal drainage is usually small as primary perito-
neal drainage is usually a temporising measure followed 
by definitive surgery or death prior to further surgery. 
Among the remaining cases exclusively treated by peri-
toneal drainage, there is no evidence to suggest that they 
would be predominantly cases of SIP.
In conclusion, the variation in NEC preventive practices 
between eight regionally defined networks of high-income 
nations was high for probiotic use and donor milk use, 
but less so for feeding practices. Despite large variabilities 
in factors known to influence NEC outcome, there was 
no significant relationship between the NEC preventive 
practice usage by units and surgical NEC rates. Overall, 
one in 25 extremely preterm neonates received NEC 
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surgery. The standardised ratios for NEC surgery were 
significantly lower in Australia/New Zealand and signifi-
cantly higher in Spain. Our results identify several areas 
of urgent research need and generates several hypotheses 
for studies aimed at improving outcome of this devas-
tating disease. It also provides a platform for evaluating 
practices using a construct of comparative effectiveness 
research whereby pragmatic evaluation of two or more 
strategies can be conducted under the umbrella of a 
registry-based pragmatic clinical trial.43 44
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